A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol

Phase 3

Terminated

• Conditions: Asthma
• Interventions: Drug: Reference Product; Drug: Placebo; Drug: Test Product

• Registration Number: NCT03562949
• Lead Sponsor: Amneal Ireland Limited

Brief Summary

To compare the efficacy and safety profiles of Beclomethasone dipropionate Inhalation Aerosol, 40 mcg (test product) and QVAR 40 mcg (beclomethasone dipropionate HFA), Inhalation Aerosol (reference product) and to demonstrate that the efficacy of the 2 active products is superior to that of placebo in the treatment of subjects with asthma.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-05-25
• Study First Submitted QC: 2018-06-18
• Study First Posted: 2018-06-20
• Study Start: 2018-12-06
• Primary Completion: 2019-08-02
• Study Completion: 2019-08-02
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-08
• Last Update Posted: 2020-01-13

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 761

Inclusion Criteria

• Adult male or female subjects of non-childbearing or of childbearing potential committing to consistent and correct use of an acceptable method of birth control.
• Diagnosis of asthma as defined by the National Asthma Education and Prevention Program at least 12 months prior to screening.
• Pre-bronchodilator FEV1 of >45% and <85% of predicted value during the screening visit and on the first day of treatment.
• >15% and >0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI).
• Patients should be stable on their chronic asthma treatment regimen for at least four weeks prior to enrollment.
• Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having had <10 pack-years of historical use.
• Ability to replace current short-acting β agonist (SABAs) with salbutamol/albuterol inhaler for use as needed for the duration of the study. Subjects should be able to withhold all inhaled SABAs for at least six hours prior to lung function assessments on study visits.
• Ability to discontinue their asthma medications (inhaled corticosteroids and long-acting β agonists) during the run-in period and for remainder of the study.
• Willingness to give their written informed consent to participate in the study.

Exclusion Criteria

• Life-threatening asthma, defined as a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma related syncopal episode(s), or hospitalizations within the past year prior to the screening or during the run-in period.
• Significant respiratory disease other than asthma (COPD, interstitial lung disease, etc.)
• Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study.
• Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle ear infection within four weeks prior to the screening, during the run-in period, or on the day of treatment.
• Hypersensitivity to any sympathomimetic drug (e.g., albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy.
• Patients receiving β2-blockers, anti-arrhythmics, anti-depressants, and monoamine oxidase inhibitors within 4 weeks prior to the screening.
• Patients who required systemic corticosteroids (for any reason) within the past 2 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Reference Product	Reference Product	Reference Product, 40 mcg, 2 x daily
Placebo	Placebo	Placebo Product 2 x daily
Test Product	Test Product	Test Product, 40 mcg, 2 x daily

Primary Outcome Measures

Name	Time	Method
Baseline-adjusted, pre-dose FEV1 on the last day of the 4-week treatment period	4 weeks	FEV1 measured in the morning prior dosing of inhaled medications on the last day of the 4-week treatment. The primary endpoint should be baseline adjusted (change from baseline).

Trial Locations

Locations (12)

San Marcus Research Clinic, Inc.; 🇺🇸 Miami Lakes, Florida, United States

Beach Clinical Research, Inc.; 🇺🇸 Huntington Beach, California, United States

Downtown La Research Center; 🇺🇸 Los Angeles, California, United States

Hope Clinical Trials, Inc.; 🇺🇸 Miami, Florida, United States

Advanced Research for Health Improvement; 🇺🇸 Naples, Florida, United States

Florida Institute for Clinical Research; 🇺🇸 Orlando, Florida, United States

Innovation Research Center; 🇺🇸 Palmetto Bay, Florida, United States

Florida Premier Research Institute; 🇺🇸 Winter Park, Florida, United States

Monroe BioMedical Research; 🇺🇸 Monroe, North Carolina, United States

TTS Research; 🇺🇸 Boerne, Texas, United States

PCP for Life/ Mercury Clinical Research; 🇺🇸 Splendora, Texas, United States

Moonshine Research Center; 🇺🇸 Doral, Florida, United States